COMMUNIQUÉS West-GlobeNewswire

AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
30/09/2026
Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in [...]
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
30/09/2026
The company is preparing to advance its drug candidate for complex perianal fistulas associated with Crohn’s disease into clinical development and aims to achieve first-in-human administration by the end of the first [...]
More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research
30/09/2026
Three published human studies cover more than 1,600 participants, all testing one complete formulation rather than its separate compounds.*† The earliest study in the set, a prospective trial of 1,236 adults, recorded a [...]
Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury
30/09/2026
Milestone Validates Proprietary Neural Repair Discovery Engine and Marks Major Expansion of First-in-Class Endothelin-B Receptor Agonist into a Critical Neurotrauma Indication with Significant Unmet Need Sovateltide is [...]
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
30/09/2026
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of [...]
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
30/09/2026
Data from BASECAMP expected in Q1 2027 TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to [...]
10 Barrel Expands Salty Sips RTD Portfolio with New Blackberry Refresher
30/09/2026
Big Blackberry Flavor Meets Low-Sugar Refreshment in the New Salty Sips Easy-Drinking Vodka Cocktail BEND, Ore., Sept. 30, 2026 (GLOBE NEWSWIRE) -- 10 Barrel Brewing , the Bend-born craft beer brand known for bold beers [...]
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
30/09/2026
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations [...]
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
30/09/2026
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m ² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, [...]
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
30/09/2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater [...]
Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers
30/09/2026
HMBD-001, a differentiated anti-HER3 monoclonal antibody discovered and developed with Hummingbird Bioscience’s AI Molecular Medicine (AIMM) platform, has advanced into Phase II clinical development Recommended doses [...]
Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society Congress
30/09/2026
New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular dystrophy compared with modelled external comparator disease trajectories derived from a single [...]
Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)
30/09/2026
Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio. Aliso Viejo, CA, Sept. 30, 2026 ( [...]
Orion Corporation completed share acquisitions
30/09/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 30 SEPTEMBER 2026 at 9.05 EEST Orion Corporation completed share acquisitions The share acquisitions [...]
Orion Corporation: Acquisition of own shares during week 40, 2026
30/09/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 30/09/2026 at 09.00 EEST Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form part of the share buyback [...]
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
30/09/2026
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its [...]
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
30/09/2026
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8 or NK cell populations. [...]

Pages